Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte to Present at Upcoming Investor Conferences

Business Wire February 17, 2015

Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs

Business Wire February 12, 2015

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer

GlobeNewswire February 11, 2015

Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine

Business Wire January 28, 2015

Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12

Business Wire January 27, 2015

Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera

Business Wire January 23, 2015

Incyte Board Appoints Two New Directors

Business Wire January 9, 2015

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

Business Wire January 9, 2015

Incyte to Present at the 33rd Annual J. P. Morgan Healthcare Conference

Business Wire December 23, 2014

Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

PR Newswire December 9, 2014

Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)

Business Wire December 2, 2014

Incyte to Present at Upcoming Investor Conferences

Business Wire November 17, 2014

Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire October 30, 2014

Incyte to Present at the Nomura BioPharma Conference

Business Wire October 23, 2014

Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer

Business Wire October 17, 2014

Incyte to Report Third Quarter 2014 Financial Results on October 30

Business Wire October 15, 2014

Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe

Business Wire October 2, 2014

Incyte to Present at the 21st Annual BioCentury NewsMakers Conference

Business Wire September 8, 2014

Join Incyte and Others to Raise Awareness of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNs) and Honor MPN Heroes

Business Wire September 8, 2014

FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted

Business Wire August 5, 2014